These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23957924)

  • 1. Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report).
    Sawai K; Goi T; Koneri K; Katayama K; Yamaguchi A
    World J Surg Oncol; 2013 Aug; 11(1):203. PubMed ID: 23957924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case study of stable disease after hepatic arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable hepatic metastases of colon cancer].
    Goi T; Nakazawa T; Koneri K; Murai A; Yamaguchi A
    Gan To Kagaku Ryoho; 2013 Oct; 40(10):1393-5. PubMed ID: 24196078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
    Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of ascending colon cancer with unresectable distant metastases treated by systemic chemotherapy].
    Sugimoto K; Tashiro Y; Nagayasu K; Niwa K; Ono S; Ishiyama S; Hata M; Komiyama H; Takahashi M; Yaginuma Y; Kojima Y; Goto M; Tanaka M; Sengoku H; Okuzawa A; Tomiki Y; Sakamoto K
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1167-70. PubMed ID: 20567130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
    Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].
    Osawa G; Yoshimatsu K; Yokomizo H; Otani T; Yano Y; Itagaki H; Matsumoto A; Fujimoto T; Umehara A; Ogawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2526-8. PubMed ID: 21224628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
    Moreau LC; Rajan R; Thirlwell MP; Alcindor T
    Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer.
    Goi T; Naruse T; Kimura Y; Fujimoto D; Morikawa M; Koneri K; Yamaguchi A
    World J Surg Oncol; 2015 Oct; 13():296. PubMed ID: 26452624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An elderly colon cancer patient with hepatic, lunge and peritoneal metastases was treated by hepatic arterial infusion and systemic chemotherapy-a case report].
    Ando M; Nagahama T; Fukuda A; Ami K; Kurokawa T; Hataji K; Ganno H; Kawasaki N; Arai K; Okada Y; Tei S
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2288-90. PubMed ID: 21224550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
    Volovat SR; Volovat C; Negru SM; Danciu M; Scripcariu V
    J Chemother; 2016 Jun; 28(3):235-41. PubMed ID: 26018108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of metastatic colon carcinoma in which a continuous intrahepatic artery-infusion of 5-FU leucovorin and cisplatin, and systemic chemotherapy with CPT-11 was very effective].
    Ishikawa T; Nakamura M; Ohkuma K; Hisano C; Nakano S; Maruyama T; Kaji Y; Niho Y; Masumoto N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1443-7. PubMed ID: 10969604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful combination therapy of radical liver resection with 5-fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case.
    Ochiai T; Masuda T; Yagi M; Kasai R; Furuyama T; Tsukamoto K; Ito H; Igari K; Aihara A; Kumagai Y; Iida M; Odajima H; Tanaka S; Arii S; Yamazaki S
    Int Surg; 2012; 97(1):6-13. PubMed ID: 23101994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.
    Chaix M; Vincent J; Lorgis V; Ghiringhelli F
    Oncology; 2014; 87(3):148-58. PubMed ID: 25012455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
    Boilève A; De Cuyper A; Larive A; Mahjoubi L; Najdawi M; Tazdait M; Gelli M; Tselikas L; Smolenschi C; Malka D; Pignon JP; Ducreux M; Boige V
    Eur J Cancer; 2020 Oct; 138():89-98. PubMed ID: 32871526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
    Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.